Interestingly, decreased BDP1 expression correlated with clinical outcomes (n = 295 samples): a metastatic event at three years (p = 7.79 × 10−7) and cancer reoccurrence at three years (p = 4.81 × 10−7) in patients with invasive breast cancer (IBC). The gene discussed is BDP1; the disease is inflammatory breast carcinoma.